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Human herpesvirus-6A and -6B uses the cellular receptor CD46 for fusion and infection of the host cell. The viral glycoprotein complex gH–
gL from HHV-6A binds to the short consensus repeat 2 and 3 in CD46. Although all the major isoforms of CD46 bind the virus, certain isoforms
may have higher affinity than others for the virus. Within recent years, elucidation of the viral complex has identified additional HHV-6A and -6B
specific glycoproteins. Thus, gH–gL associates with a gQ1–gQ2 dimer to form a heterotetrameric complex. In addition, a novel complex
consisting of gH–gL–gO has been described that does not bind CD46. Accumulating evidence suggests that an additional HHV-6A and -6B
receptor exists. The previous simple picture of HHV-6A/B-host cell contact therefore includes more layers of complexities on both the viral and
the host cell side of the interaction.
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initiated by the interaction of a viral protein with a cellular
receptor. For many viruses, this simplistic view is conceptua-
lized in the search of the receptor for a given virus. In the
case of human herpesvirus-6A and -6B, the conundrum was
thought to be solved with the identification of CD46 as a
receptor interacting with the viral glycoproteins gH–gL.
However, emerging data have taught us that deciphering
HHV-6A and -6B interaction with the cellular surface receptor
(s) is far more complicated than initially assumed, and once
again stressed that HHV-6A and HHV-6B behave as inde-
pendent viruses.
Isoforms of cellular receptors
HHV-6A and -6B are characterized by a relatively broad
tropism for different human cells, whereas the species
specificity is narrow with only few susceptible nonhuman
primates. The discovery by Lusso and colleagues of CD46 as a
HHV-6A/B receptor provided some of the explanations to these
findings (Santoro et al., 1999). CD46 is remarkable in that it is a
receptor for a large variety of microorganisms including⁎ Corresponding author. Fax: +45 8619 6128.
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doi:10.1016/j.virol.2006.07.028measles virus, all species B adenoviruses except types 3 and
7, Streptococcus pyogenes, Neisseria gonorrhoea, and Neis-
seria meningitides (Liszewski et al., 2005). The structure of
CD46 contains 4 short consensus repeats (SCR), each including
4 cysteines that form two conserved disulfide bonds, a serine–
threonine–proline rich domain (ST), a sequence of unknown
significance, a transmembrane region (TM) and a cytoplasmic
sequence (CYT) (Fig. 1). The CD46 gene comprises 14 exons
and gives rise to a number of isoforms caused by alternative
splicing of the ST, TM and CYT domains, whereas the SCR
domains are constant. CD46 is ubiquitously expressed on all
nucleated cells and belongs to a family of regulators of
complement activation.
Using deletion mutants of CD46, Mori et al. identified
SCR2, SCR3, and SCR4 as binding site for HHV-6A strain
U1102 (HHV-6AU1102) (Mori et al., 2002). The necessity of
SCR4 remains controversial, since Greenstone et al. using a
number of truncations and molecular chimeras of CD46 and
DAF (CD55) identified SCR2 and SCR3 as the binding
domain for HHV-6AGS (Greenstone et al., 2002). Indeed,
Mori et al. were able to block fusion of HHV-6AGS by
antibodies specific for SCR2 and 3, but not by antibodies
against SCR1 (Mori et al., 2002). Despite the presence of
SCR in DAF, which also belongs to the family of regulators
of complement activation, they do not function as a receptor
Fig. 1. Complexities in HHV-6A/B glycoprotein interactions with cellular
receptors. The tetrameric complex gH–gH–gQ1–gQ2 may interact with CD46
and potentially other cellular receptors. HHV-6A (and probably HHV-6B) binds
to the short consensus repeats (SCR) 2 and 3. The complex gH–gL–gO does not
bind to or may have low affinity for CD46. In contrast, this complex may
interact with a novel HHV-6A/B receptor. It remains to be determined whether
HHV-6B is quantitatively or qualitatively different from HHV-6A. See text for
further details.
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exons denoted A, B, and C. Although all the major isoforms
of the ST domain in CD46 bind HHV-6AU1102, they do so
with different affinities with STC and STBC being the most
effective as receptors for induction of fusion (Mori et al.,
2002). HHV-6B is also dependent on CD46 for fusion, but
whether or not it uses the same SCRs as HHV-6A has not
been addressed.Multiple viral protein complexes
In HHV-6A and -6B, as well as in other β-herpesviruses,
gH and gL form a complex via intermolecular disulfide
bridges, which is important for cell fusion events. However,
the HHV-6A glycoprotein complex turned out to include
additional proteins. Mori and colleagues defined two major
proteins encoded by the HHV-6AGS U100 gene (Akkapai-
boon et al., 2004). These proteins of 80 kDa and 37 kDa,
denoted gQ1 and gQ2, form dimers within the cell and later
interact with the gH–gL complex to form a tetrameric viral
complex. Neither gQ1 nor gQ2 are predicted to contain a
transmembrane region and they may be transported via
association with gH. The stoichiometry of these interactions
remains to be determined. Thus, it is not yet clear to what
extent other forms of this complex may exist, e.g. gH–gL or
gH–gL–gQ1. In analogy, infection of B cells by EBV
requires the association of gp42 with the gH–gL complex,
which then binds to HLA class II receptor on the host cell.
However, during EBV infection of epithelial cells, gp42 is not
needed and gH–gL binds a yet unknown receptor. It is
therefore an interesting possibility that gH–gL alone or indifferent combinations may have affinity for different cellular
receptors.
Cell-specific differences in glycosylation and
post-transcriptional modifications
The discovery of an interaction between gH–gL and gQ
proteins opens for additional complexities. The organization of
the U100 gene is the most complex in the HHV-6A/B genome
with an intron–exon structure that gives rise to multiply spliced
mRNA transcripts. We do not know how gQ1–gQ2 form a
heterodimer nor do we know how this dimer associates with the
gH–gL heterodimer. Both of these gQ proteins have multiple
potential N-linked glycosylation sites with prediction of 6 in
gQ1 and 4 in gQ2. The broad range of HHV-6A/B tropism may
allow for additional variation in cell-specific glycosylation
patterns, which ultimately may affect the composition of the
viral attachment/entry complex.
Likewise, the CD46 receptor contains N-linked glycosyla-
tions in SCR1, 2 and 4, and is heavily O-linked glycosylated
in the ST domain. Although the B exon of ST is encoding
only 15 amino acids, the majority of O-linked glycosylation
sites are within this sequence (Post et al., 1991). Importantly,
the distribution of STBC and STC is tissue specific with STBC
being the predominant form expressed in the salivary glands
and STC being predominantly expressed in the brain
(Johnstone et al., 1993). Indeed, both HHV-6A and -6B
may infect the brain, but HHV-6A is thought to be more
neurotropic than HHV-6B (De Bolle et al., 2005; Ahlqvist et
al., 2005). In contrast, HHV-6B may be more predominantly
expressed in the salivary glands. Whether these differences in
tropism are influenced by isoforms of the ST domain and
thereby by differences in O-linked glycosylation of CD46
remain to be investigated. HHV-6A and HHV-6B also display
differences in tropism for T lymphocytes with HHV-6A
infecting both CD4+ and CD8+ T cells, whereas HHV-6B
appears to be inefficient in infecting CD8+ T cells (Grivel et
al., 2003). Peripheral blood lymphocytes may contain both
the STBC and STC isoform. Thus, the role of CD46
glycosylation during HHV-6A and -6B binding to host cells
remains to be established.
Genetic differences between viral strains and variants
Whereas the gH–gL–gQ1–gQ2 complex is a receptor for
HHV-6AGS, its role as a receptor for the HHV-6B variants is less
clear. The U100 gene is located in a region of the HHV-6A/B
genome with the greatest variability between HHV-6A and -6B
variants. Thus HHV-6BZ29 differs up to 17% in certain exons
from HHV-6AU1102, whereas HHV-6BHST differs by up to 28%
at the nucleotide level (Dominguez et al., 1999; Isegawa et al.,
1999).
Alternative cellular receptors
The identification of CD46 as a receptor for HHV-6A/B
did not entirely explain all the experimental evidence that had
3Minireviewaccumulated on HHV-6A and -6B attachment and entry.
Lusso and colleagues found that a panel of human CD4+ T-
cell lines showed diversity in their ability to be infected by
HHV-6AGS and subsequently fuse. This was not due to
separate isoforms of CD46, as transfection of CD46 did not
make these cells sensitive for fusion or infection. In contrast,
these cells did fuse upon infection with measles virus,
strongly suggesting the existence of a novel receptor (Santoro
et al., 1999). In this respect, it is interesting that Mori et al.
have also identified a novel trimer consisting of gH–gL in
complex with the U47 gene product, gO (Mori et al., 2004).
Importantly, the gH–gL–gO complex has been found on both
HHV-6AGS and HHV-6BHST virions, but surprisingly the
HHV-6BHST gH–gL–gO or gH–gL–gQ complexes did not
bind CD46, and only the complex containing gQ on HHV-
6AGS bound CD46. This suggests that gH–gL–gO may be a
viral complex for a novel cellular receptor. One should,
however, be careful with the interpretation of the lack of
CD46 binding of HHV-6BHST, since HHV-6BPL-1 and HHV-
6BZ29 clearly use CD46 (Pedersen et al., in press; Santoro et
al., 1999). Nevertheless, these findings may either reflect
differences in the affinity towards CD46 between the variants
and perhaps even between strains within a variant, or the
dependency of additional receptors, or both.
What began as a simple one viral protein versus one
cellular receptor has broadened substantially in complexity.
With a “backbone” of gH–gL as other herpesviruses, HHV-
6A and -6B incorporate additional HHV-6A/B-specific
glycoproteins to form multichain complexes to adhere, fuse
and enter the host cells. There may be further surprises
ahead in the composition of this complex, as the recruited
glycoproteins originate from highly spliced genes in the
virus, and the glycoproteins contain multiple potential
glycosylation sites that may lead to different glycosylation
or other post-translational modifications in different host
cells. In addition, the receptor being recognized is subject to
multiple isoforms, and although HHV-6AU1102 may bind to
all of them, it does so with different affinity. Finally,
evidence indicates that at least one yet unknown cellular
receptor must exist to explain the differences between the
HHV-6A and -6B variants.References
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